News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 

Full Suite of Cxbladder Tests Adopted by DHB

Full Suite of Cxbladder Tests Adopted by New Zealand Public Healthcare Provider Capital & Coast Dhb
Pacific Edge signs agreement with Capital & Coast District Health Board, providing access to full suite of Cxbladder products

Cancer diagnostics company, Pacific Edge (NZX: PEB), has entered into an agreement with one of New Zealand’s largest public healthcare providers, Capital & Coast District Health Board (CCDHB), to provide its suite of Cxbladder cancer diagnostic tests for the detection, management and monitoring of bladder cancer patients.

CCDHB is the latest in a rapidly expanding list of New Zealand public healthcare providers to incorporate Cxbladder into their clinical pathways for urology services including the recent signing of public healthcare providers Counties Manukau and Tairawhiti DHBs which have signed agreements within the last quarter. These new commercial users join the existing public healthcare providers in Canterbury, Bay Of Plenty/Lakes, MidCentral and Waitemata in their use of Cxbladder, bringing the total coverage of New Zealand’s population under contract to more than 60%.

The full suite of easy-to-use, accurate and non-invasive Cxbladder urine tests will be used by CCDHB healthcare professionals at key decision points in the bladder cancer clinical pathway, from evaluation of blood in the urine (haematuria) a key indicator of bladder cancer, through to management and monitoring for recurrence of the disease.

Brent Pownall, VP Commercial and Franchise at Pacific Edge, said: “Capital and Coast DHB have been using Cxbladder on a limited scale now for a few years, and are very familiar with the different applications for the tests. Armed with the Cxbladder test results, we are confident they can safely and effectively change the way they manage haematuria referrals and bladder cancer surveillance for patients in the greater Wellington region, with the clear benefit for patients identified as not requiring an invasive cystoscopy procedure.

“This is another significant commercial milestone in our goal to make Cxbladder the urologists’ preferred diagnostic tool across the clinical pathway for haematuria and bladder cancer follow-up for New Zealand physicians and patients alike. Today’s agreement with CCDHB provides coverage for patients for all four Cxbladder products.”

ENDS

© Scoop Media

 
 
 
Culture Headlines | Health Headlines | Education Headlines

 


Howard Davis Review: Pretty Maids All In A Row - Mary Queen of Scots

The disproportionate attention paid by the film industry to a figure of minor historical significance once again confirms that any story involving sex, murder, and political intrigue will always trump historical accuracy at the box office. More>>

Howard Davis Review: Wild at Heart - The Happy Prince and At Eternity's Gate

Besides being exact contemporaries who were born and died prematurely within a year of each other, Oscar Wilde and Vincent van Gogh shared the cautionary experience of being outcast and repudiated in their brief lifetimes. More>>

"Our Pride": Auckland Pride 2019 Programme Announcement

Auckland Pride Festival returns in 2019, celebrating the diversity of the rainbow experience in Tāmaki Makaurau and reconnecting with grassroots communities across the region, fromFebruary 1-17. More>>

ALSO:



Sir Stephen Robert Tindall, KNZM"Congratulations To Our Honours Recipients"

One hundred and ninety six New Zealanders were congratulated by Prime Minister Jacinda Ardern for their contributions to New Zealand and our communities… More>>

ALSO:

 
 
 
 
 

LATEST HEADLINES

  • CULTURE
  • HEALTH
  • EDUCATION
 
 
  • Wellington
  • Christchurch
  • Auckland